1. Home
  2. ANIX vs TTEC Comparison

ANIX vs TTEC Comparison

Compare ANIX & TTEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.42

Market Cap

119.8M

Sector

Health Care

ML Signal

HOLD

Logo TTEC Holdings Inc.

TTEC

TTEC Holdings Inc.

HOLD

Current Price

$2.55

Market Cap

109.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
TTEC
Founded
1982
1982
Country
United States
United States
Employees
N/A
69400
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
119.8M
109.0M
IPO Year
2013
1996

Fundamental Metrics

Financial Performance
Metric
ANIX
TTEC
Price
$3.42
$2.55
Analyst Decision
Strong Buy
Hold
Analyst Count
3
2
Target Price
$8.67
N/A
AVG Volume (30 Days)
245.1K
359.9K
Earning Date
05-27-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
12.82
40.80
EPS
N/A
N/A
Revenue
$210,000.00
$1,509,171,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$0.10
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.15
52 Week Low
$2.32
$1.91
52 Week High
$5.46
$3.99

Technical Indicators

Market Signals
Indicator
ANIX
TTEC
Relative Strength Index (RSI) 55.02 60.80
Support Level $2.77 $2.42
Resistance Level $3.53 $2.66
Average True Range (ATR) 0.25 0.14
MACD -0.04 0.05
Stochastic Oscillator 20.69 79.31

Price Performance

Historical Comparison
ANIX
TTEC

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About TTEC TTEC Holdings Inc.

TTEC Holdings Inc provides customer engagement management tools and services. The company operates through two operating segment, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and its revenues are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.

Share on Social Networks: